Bioatla, INC. (BCAB) — 8-K Filings

8-K Filings (19)

• BioAtla 8-K: Officer/Director Changes & Shareholder Vote — Mar 23, 2026
  BioAtla, Inc. filed an 8-K on March 23, 2026, reporting events from March 17, 2026, under Item 5.02 and Item 5.07. Item 5.02 covers changes in directors or offi
• BioAtla Files 8-K: Material Agreement, Equity Sales — Dec 31, 2025 Risk: medium
  BioAtla, Inc. filed an 8-K on December 31, 2025, reporting on events that occurred on December 30, 2025. The filing indicates an entry into a material definitiv
• BioAtla Files 8-K for Shareholder Vote and Other Events — Dec 30, 2025 Risk: low
  BioAtla, Inc. filed an 8-K on December 30, 2025, to report on the submission of matters to a vote of security holders and other events. The filing does not cont
• BioAtla Enters Material Definitive Agreement — Nov 21, 2025 Risk: medium
  On November 20, 2025, BioAtla, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware,
• BioAtla, Inc. Files 8-K Under 'Other Events' — Sep 22, 2025 Risk: medium
  BioAtla, Inc. filed an 8-K on September 22, 2025, reporting an event that occurred on September 16, 2025. The filing is categorized under 'Other Events' and doe
• Bain Capital to Acquire BioAtla for $1.00/Share — Jun 20, 2025 Risk: medium
  BioAtla, Inc. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Bain Capital Life Sciences for $1.00
• BioAtla Faces Delisting Concerns — May 16, 2025 Risk: high
  BioAtla, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event
• BioAtla, Inc. Files 8-K Report — Mar 27, 2025 Risk: low
  On March 27, 2025, BioAtla, Inc. filed an 8-K report detailing financial results and other material information. The filing indicates the company's principal ex
• BioAtla Appoints New CEO, CMO, and Directors — Mar 14, 2025 Risk: medium
  BioAtla, Inc. announced on March 11, 2025, changes in its executive and director roles. Dr. Jay L. Short has been appointed as Chief Executive Officer and Presi
• BioAtla Faces Delisting Concerns — Feb 7, 2025 Risk: high
  BioAtla, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective February 6
• BioAtla Files 8-K for Reg FD and Financials — Dec 20, 2024 Risk: low
  BioAtla, Inc. filed an 8-K on December 20, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing details the
• BioAtla Files 8-K for Material Agreement — Sep 23, 2024 Risk: medium
  On September 23, 2024, BioAtla, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits r
• BioAtla, Inc. Reports on Shareholder Vote Matters — Jun 13, 2024 Risk: low
  BioAtla, Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain details about
• BioAtla Files 8-K: Other Events — May 17, 2024 Risk: low
  BioAtla, Inc. filed an 8-K on May 17, 2024, reporting an event that occurred on May 15, 2024. The filing is categorized under 'Other Events' and does not specif
• BioAtla Files 8-K with Bylaw Amendments and Exhibits — Apr 24, 2024 Risk: low
  On April 22, 2024, BioAtla, Inc. filed an 8-K report detailing amendments to its articles of incorporation and bylaws. The filing also included financial statem
• BioAtla Reports Executive Changes and Compensation Arrangements — Feb 21, 2024 Risk: medium
  BioAtla, Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to Item 5.02, which covers the depar
• BioAtla (BCAB) Files Routine 8-K for 'Other Event' — Feb 12, 2024 Risk: low
  BioAtla, Inc. (BCAB) filed an 8-K on February 12, 2024, reporting an 'Other Event' that occurred on February 6, 2024. This filing is a routine disclosure indica
• BioAtla Files 8-K for Regulation FD Disclosure, Exhibits — Jan 9, 2024
  BioAtla, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing, under
• BioAtla (BCAB) Announces 1-for-20 Reverse Stock Split — Jan 8, 2024
  On January 5, 2024, BioAtla, Inc. (BCAB) filed an 8-K to report amendments to its Certificate of Incorporation, specifically implementing a reverse stock split

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX